{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:24:57Z","timestamp":1787246697496,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01836-5","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:30:38Z","timestamp":1782207038000},"page":"3813-3829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Modalities of Combined Medical and Surgical Treatment in Hidradenitis Suppurativa: A Systematic Review of Efficacy and Safety"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-4748","authenticated-orcid":false,"given":"Laura","family":"Mateu-Arrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-0534","authenticated-orcid":false,"given":"Eva","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"10476","key":"1836_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025;405(10476):420\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(24)02475-9.","journal-title":"Lancet"},{"issue":"10","key":"1836_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/ced\/llae120","volume":"49","author":"SA Merchant","year":"2024","unstructured":"Merchant SA, Shah SFH. The impact of hidradenitis suppurativa on work productivity and performance: a systematic review and meta-analysis. Clin Exp Dermatol. 2024;49(10):1156\u201363. https:\/\/doi.org\/10.1093\/ced\/llae120.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1836_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jdv.20472","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899\u2013941. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1836_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000511045","volume":"237","author":"A Gonz\u00e1lez-Manso","year":"2021","unstructured":"Gonz\u00e1lez-Manso A, Agut-Busquet E, Roman\u00ed J, et al. Hidradenitis suppurativa: proposal of classification in two endotypes with two-step cluster analysis. Dermatology. 2021;237(3):365\u201371. https:\/\/doi.org\/10.1159\/000511045.","journal-title":"Dermatology"},{"issue":"4","key":"1836_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.13090","volume":"171","author":"CB Kromann","year":"2014","unstructured":"Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GBE. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171(4):819\u201324. https:\/\/doi.org\/10.1111\/bjd.13090.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1836_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"key":"1836_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1836_CR8","unstructured":"Development group for ROBINS-I V2. Risk of bias tools\u2014ROBINS-I V2 tool. https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/robins-i-v2. Accessed 17 Feb 2026."},{"key":"1836_CR9","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","DOI":"10.1136\/bmj.i4919"},{"issue":"12","key":"1836_CR10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1111\/1346-8138.17375","volume":"51","author":"PT Lai","year":"2024","unstructured":"Lai PT, Tseng HC. Adopting adalimumab combined surgery in the management of moderate to severe hidradenitis suppurativa: Experience from a single medical center in southern Taiwan. J Dermatol. 2024;51(12):1615\u201321. https:\/\/doi.org\/10.1111\/1346-8138.17375.","journal-title":"J Dermatol"},{"issue":"4","key":"1836_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaad.2023.04.034","volume":"89","author":"P Aarts","year":"2023","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol. 2023;89(4):677\u201384. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.034.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1836_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG, Podda M, Prens EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2021.3655.","journal-title":"JAMA Surg"},{"issue":"7","key":"1836_CR13","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/DSS.0000000000004604","volume":"51","author":"TT Vu","year":"2025","unstructured":"Vu TT, Soong LC, Hagtvedt R, Keeling CP. Surgical deroofing in the management of hidradenitis suppurativa alone or as an adjunct to medical therapies. Dermatol Surg. 2025;51(7):e17\u201321. https:\/\/doi.org\/10.1097\/DSS.0000000000004604.","journal-title":"Dermatol Surg"},{"key":"1836_CR14","doi-asserted-by":"publisher","first-page":"14493","DOI":"10.2147\/JIR.S554170","volume":"18","author":"X Liu","year":"2025","unstructured":"Liu X, Yuan C, Kang Y, et al. Analysis of the efficacy and safety of secukinumab combined with surgical treatment for hidradenitis suppurativa: a real-world retrospective study in China. J Inflamm Res. 2025;18:14493\u2013502. https:\/\/doi.org\/10.2147\/JIR.S554170.","journal-title":"J Inflamm Res"},{"key":"1836_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jdin.2025.08.014","volume":"24","author":"Q Xu","year":"2026","unstructured":"Xu Q, Xie Y, Chen Z, et al. Combination secukinumab and surgical intervention for moderate-to-severe hidradenitis suppurativa: a retrospective cohort study. JAAD Int. 2026;24:234\u20136. https:\/\/doi.org\/10.1016\/j.jdin.2025.08.014.","journal-title":"JAAD Int"},{"issue":"11","key":"1836_CR16","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s13555-025-01521-z","volume":"15","author":"M Mansilla-Polo","year":"2025","unstructured":"Mansilla-Polo M, Garc\u00eda-Moronta C, Fern\u00e1ndez-Crehuet P, et al. Long-term effectiveness and safety of bimekizumab in patients with moderate to severe hidradenitis suppurativa under real clinical practice conditions: the importance of combined treatment in Hurley\u00a0III patients and potential factors associated with complete response. Dermatol Ther (Heidelb). 2025;15(11):3267\u201383. https:\/\/doi.org\/10.1007\/s13555-025-01521-z.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1836_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.23736\/S2784-8671.24.07620-5","volume":"159","author":"D Malvaso","year":"2024","unstructured":"Malvaso D, Chiricozzi A, Fossati B, Antonelli F, Peris K. Efficacy and safety of a combined pharmacological and surgical approach in patients affected by hidradenitis suppurativa: data from a retrospective real-world clinical study. Ital J Dermatol Venereol. 2024;159(2):190\u20135. https:\/\/doi.org\/10.23736\/S2784-8671.24.07620-5.","journal-title":"Ital J Dermatol Venereol"},{"key":"1836_CR18","doi-asserted-by":"publisher","unstructured":"Molinelli E, Febi D, De Simoni E, et al. A narrative review of local therapies in hidradenitis suppurativa: treatment landscape and current issues. Dermatol Ther (Heidelb). 2026;16(4):1869\u201387. https:\/\/doi.org\/10.1007\/s13555-026-01712-2.","DOI":"10.1007\/s13555-026-01712-2"},{"issue":"7","key":"1836_CR19","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s13555-023-00954-8","volume":"13","author":"M Oliveira","year":"2023","unstructured":"Oliveira M, Rahawi K, Duan Y, Lane M, Amin AZ, Sayed CJ. Effect of biologics on the need for procedural interventions, systemic medications, and healthcare utilization in patients with hidradenitis suppurativa: real-world data from the UNITE Registry. Dermatol Ther (Heidelb). 2023;13(7):1577\u201385. https:\/\/doi.org\/10.1007\/s13555-023-00954-8.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1836_CR20","doi-asserted-by":"publisher","unstructured":"Martorell A, Vilarrasa-Rull E, Fernandez-Crehuet P, et al. Real-world experience with secukinumab for hidradenitis suppurativa: a multicenter retrospective analysis of 263 patients from the SECU-SPAIN study. Actas Dermosifiliogr. 2026;117(4):104562. https:\/\/doi.org\/10.1016\/j.ad.2025.104562.","DOI":"10.1016\/j.ad.2025.104562"},{"issue":"4","key":"1836_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/JAMADERMATOL.2022.6266","volume":"159","author":"H Bui","year":"2023","unstructured":"Bui H, Bechara FG, George R, et al. surgical procedural definitions for hidradenitis suppurativa developed by expert Delphi consensus. JAMA Dermatol. 2023;159(4):441\u20137. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2022.6266.","journal-title":"JAMA Dermatol"},{"key":"1836_CR22","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Barba D, S\u00e1nchez D\u00edaz M, Montero V\u00edlchez T, Molina Leyva A, Arias Santiago S. Is there a surgical window of opportunity in hidradenitis suppurativa? Int Wound J. 2024;21(6):e14885. https:\/\/doi.org\/10.1111\/iwj.14885.","DOI":"10.1111\/iwj.14885"},{"issue":"1","key":"1836_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jdds.2016.09.001","volume":"21","author":"M Ritsu","year":"2017","unstructured":"Ritsu M, Kawakami K, Kanno E, et al. Critical role of tumor necrosis factor-\u03b1 in the early process of wound healing in skin. J Dermatol Dermatol Surg. 2017;21(1):14\u20139. https:\/\/doi.org\/10.1016\/j.jdds.2016.09.001.","journal-title":"J Dermatol Dermatol Surg"},{"issue":"5","key":"1836_CR24","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","volume":"73","author":"E Prens","year":"2015","unstructured":"Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5):S8\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.045.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1836_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.911.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1836_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/iwj.13241","volume":"17","author":"LM Ngaage","year":"2019","unstructured":"Ngaage LM, Wu Y, Ge S, et al. Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision. Int Wound J. 2019;17(1):117. https:\/\/doi.org\/10.1111\/iwj.13241.","journal-title":"Int Wound J"},{"key":"1836_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jbcr\/irag035","author":"KS Garg","year":"2026","unstructured":"Garg KS, Le TD, Pinto D, et al. Predictors for remission versus refractory disease following wide local excision surgery for hidradenitis suppurativa: a single-center case\u2013control analysis. J Burn Care Res. 2026. https:\/\/doi.org\/10.1093\/jbcr\/irag035.","journal-title":"J Burn Care Res"},{"issue":"9853","key":"1836_CR28","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605. https:\/\/doi.org\/10.1016\/S0140-6736(12)60026-9.","journal-title":"Lancet"},{"issue":"2","key":"1836_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104(2):465\u201383. https:\/\/doi.org\/10.1038\/ajg.2008.168.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1836_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.mcna.2020.09.011","volume":"105","author":"D Zisa","year":"2021","unstructured":"Zisa D, Goodman SM. Perioperative management of rheumatic disease and therapies. Med Clin North Am. 2021;105(2):273\u201384. https:\/\/doi.org\/10.1016\/j.mcna.2020.09.011.","journal-title":"Med Clin North Am"},{"key":"1836_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03316-2","author":"AV Marzano","year":"2024","unstructured":"Marzano AV, Magnoni C, Micali G, et al. Improving hidradenitis suppurativa management: consensus statements from physicians and patients\u2019 perspectives. Arch Dermatol Res. 2024;316(8):577. https:\/\/doi.org\/10.1007\/s00403-024-03316-2.","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01836-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01836-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:05Z","timestamp":1787243405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01836-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1836"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01836-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Laura Mateu-Arrom has received honoraria as a speaker from Novartis and support for meeting attendance from Novartis, Almirall, and UCB. Alejandro Molina-Leyva has received support for attending meetings, served as an advisory board member, and participated in clinical trials from Abbvie, Novartis, Moonlake, MSD, Sanofi, Incyte Almirall, and UCB. Eva Vilarrasa has received honoraria and\/or travel grants and\/or has served as an advisory board member and\/or has participated in clinical trials sponsored by Abbvie, Aceleryn, Almirall, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Citryll, Gebro, Incyte, Isdin, Janssen, Leo-Pharma, Lilly, Merck-Serono, MoonLake, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, Takeda, UCB. She also has worked as consultant or contributed to the development or participated in clinical trials for iDermApp, Mediktor, DermUS, Biomi, HSCalc, and BHH.\u00a0Alejandro Molina-Leyva and Eva Vilarrasa are Editorial Board members of\u00a0\n                      Dermatology and Therapy\n                      . Alejandro Molina-Leyva and Eva Vilarrasa were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}